A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain

Cristina Nativi1,2, Roberta Gualdani1, Elisa Drago1, Lorenzo Di Cesare Mannelli3, Silvia Sostegni1, Martina Norcini1, Gabriele Gabrielli1, Giancarlo Ia Marca2, Barbara Richichi1, Oscar Francesconi1, Maria Rosa Moncelli1, Carla Ghelardini3 & Stefano Roelens4

1Dipartimento di Chimica, Università di Firenze, Polo Scientifico e Tecnologico, Via della Lastruccia 13, I–50019 Sesto Fiorentino, Firenze, Italy, 2FiorGen, Università di Firenze, via Sacconi, 6 I-50019 Sesto Fiorentino, Italy, 3Dipartimento NeuroFarBa, V.le G. Pieraccini 6, I-50139 Firenze, Italy, 4Istituto di Metodologie Chimiche (IMC), Consiglio Nazionale delle Ricerche (CNR), Dipartimento di Chimica, Università di Firenze, Polo Scientifico e Tecnologico, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Firenze, Italy.

Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.

Pain is the evolved response to noxious stimuli1; it plays an important role in safeguarding the individual from potential sources of tissue destruction. However, the perception of pain can also be the result of a dysfunction of the nervous system. Typically, local injury or infections trigger the release of peripheral chemical mediators eliciting two diverse effects: (a) activate the inflammatory response attracting leukocytes to the point of injury, and (b) sensitize nociceptors (neurons responsible for the transmission of pain) enhancing their response to pain. Under some circumstances, however, nociceptor activity diverge from normal physiology and pain is produced in the absence of any appropriate stimulus. This is known as pathological pain or neuropathic pain (NeP). NeP can be caused by lesions to the central or peripheral nervous system, or can be induced by metabolic insult or trauma, autoimmune diseases, infections (e.g., HIV-1), diabetes, cancer, or it can be the consequence of the toxic side-effects of diverse drug regimens. From the behavioral point of view, NeP is a chronic algic sensation associated with altered sensibility, including allodynia (pain evoked by an innocuous stimulus) and hyperalgesia (amplified pain induced by a noxious stimulus), and with loss of functionality2–4. In states of NeP, the protective role of pain is lost, because the abnormal activity of nociceptive neurons does not offer biological advantage but just causes suffering and distress. Although nociceptors signal alteration is still a matter of debate, this abnormal activity of nociceptive neurons is thought to result from the increased neuronal expression and activation of ion channels and receptors that initiate and mediate the abnormal generation of action potentials and synaptic transmission in pain pathways5.

Therapeutically, NeP is considered an intractable problem. As a matter of fact, it is not readily treated with nonsteroidal anti-inflammatory drugs, whereas tricyclic antidepressants and antiepileptics are not particularly effective, while being associated with several negative side effects6. Conversely, opiates might be used for acute or chronic pains, e.g., in terminal cancer; yet, alleviation of NeP remains problematic because of the side-effects associated with opioid analgesia, such as opioid-like withdrawal and physical dependence, and because of the high doses often required, which reduce the gap between the effective and lethal dose (therapeutic index)7. These therapeutic limitations are particularly severe in commonly occurring situations, such as in the chronic NeP that is frequently observed in patients receiving antitumoral chemotherapy8. Treatment of this pain status is becoming compelling, since the development of new anticancer drugs will conceivably extend the survival of tumor-bearing...
hosts, so that neurotoxicity rather than tumor progression may become the treatment-limiting issue in the therapy of some kind of cancer. At present, clinical use of highly effective chemotherapeutics, such as oxaliplatin, cisplatin, vincristine and paclitaxel, is severely compromised by the development of painful peripheral neuropathy, consisting of mechanical and cold allodynia, ongoing burning pain, tingling numbness, allodynic sensation in hands and feet, and chronic foot/leg, hand/arm numbness. Although these chemotherapeutic agents have different neurotoxicity profiles, they all produce painful effects that are very often responsible for therapy interruption. It is thus clear that the availability of safe and effective analgesic drugs that may be used for the treatment of chronic neuropathic pain (NeP) is a target of high interest and of urgent need.

Acute and chronic neuropathic pain has been thoroughly described. Recently, chronic oxaliplatin-induced neuropathy has been related to changes in the expression and sensitivity of transient receptors potential (TRP) and other cation channels. In particular, the role of TRPA1 as a sensor of reactive compounds, such as those generated during oxidative stress caused by oxaliplatin and cisplatin administration, has been firmly established. Furthermore, it has been reported that oxaliplatin-evoked allodynia and NeP in rats are mediated by TRPA1 and that channel activation is likely caused by glutathione-sensitive molecules.

In this context, we describe herein an easily accessible, water-soluble derivative of lipoic acid, named ADM_09, which proved to be remarkably effective in the treatment of oxaliplatin-induced neuropathy without eliciting the most common negative side-effects. In our studies, we investigated the anti-oxidative properties of ADM_09 in vitro and in cellular systems, and we established the ability of ADM_09 to revert oxaliplatin-induced NeP in vivo. ADM_09 was also found devoid of any cardiotoxicity and of toxic effects toward astrocytes. Whole-cell patch clamp recordings demonstrated that ADM_09 is an effective antagonist of the TRPA1 receptor, showing inhibition activity in the low micromolar range; a mode of action fitting the experimental evidence has been proposed for the observed blocking activity.

**Results**

Synthesis. ADM_09 was synthesized in two steps from commercially available (±)-α-lipoic acid and L-carnosine under very mild conditions (Fig. 1). The antioxidative and mild analgesic properties of lipoic acid are well documented; for example, lipoic acid has been shown to reduce oxaliplatin-induced hyperalgesia in rats through anti-oxidative processes. On the other hand, carnosine has been proven to scavenge reactive oxygen species (ROS) as well as α,β-unsaturated aldehydes formed from peroxidation of cell membrane fatty acids during oxidative stress. The design of ADM_09 was aimed at achieving a synergic combination of the two substrates through their incorporation into a single compound, with the goal of obtaining an enhancement of their antioxidative and analgesic properties. (±)-α-Lipoic acid was activated by reacting with N-hydroxysuccinimide to form the corresponding ester, which was used to room temperature with L-carnosine in the presence of sodium bicarbonate to afford ADM_09 in 73% overall yield as a crystalline sodium salt (Fig. 1).

ADM_09 is a low molecular weight compound, soluble in water, stable under acidic (pH 1) and alkaline (pH 10) conditions, in saliva, and at room temperature and 37°C. ADM_09 did not show acute toxicity and fulfills the requirements of the so-called “rule of five” for drug-likeness.

To ascertain whether the two diastereomeric forms of ADM_09 would possess different biological activities, RADM_09 and SADM_09 were prepared as diastereomerically pure compounds by reacting L-carnosine with enantiomerically pure (R)-(+) and (S)-(−)-α-lipoic acid, respectively (Fig. 1).

**Antioxidative properties.** The antioxidant profile of ADM_09 was evaluated *in vitro* by measuring the oxidation of nitro blue tetrazolium (NBT) after 30 min, in the absence and in the presence of an increasing concentration of ADM_09 (Table S1, Supporting Information). The superoxide anion (O2−) generated by the hypoxanthine–xanthine oxidase system increased the oxidized NBT level from 100 (basal) to 4000 A.U. In the presence of ADM_09 in the reaction mixture, the oxidation of NBT was inhibited in a concentration-dependent manner. For example, 100 μM ADM_09 decreased the oxidized NBT from 4000 to 3200 A.U. (see Table S1), indicating a detectable antioxidative activity. However, comparing the efficacy of ADM_09 with other commonly employed antioxidants, including lipoic acid, it is easily appreciated that its antioxidative properties are only moderate and, notably, markedly less effective than the parent lipoic acid (Fig. 2). Apparently, coupling of lipoic acid with carnosine affected the antioxidative capability of the former residue, inducing a significant loss of activity.

The antioxidative properties of ADM_09 were also tested in vivo in rat cortical astrocytes. Because glial cells exert a pivotal role in the development of neuropathic pain, astrocytes from primary cultures were used in the antioxidative tests, as these are directly related to

![Figure 1](https://example.com/f1.png)
normal tissues. In primary cultures of astrocytes, the neurotoxic compound OXA (100 μM) induced a significant, SOD-inhibitable, superoxide anion increase after 4 h incubation, as evaluated by the cytochrome C assay (Fig. 3). Co-incubation with 100 μM ADM_09 inhibited the O2·− formation by over 50% with respect to the untreated culture.

Overall, these data indicate that ADM_09 possess antioxidative properties that may be beneficial for the OXA-induced oxidative stress, although showing lower activity compared to the parent lipoic acid.

Antihyperalgesic properties. The efficacy of ADM_09 against NeP was tested in vivo by monitoring the response to a suprathreshold stimulation (hyperalgesia-related measure) in laboratory animals through the paw-pressure test. OXA (2.4 mg/kg, i.p.) was administered daily to rats for 21 days according to the Cavaletti procedure. To the treated rats, ADM_09 (10–120 mg/kg) was administered orally (p.o., vehicle: 1% CMC), following the effects at intervals from 15 to 120 min after administration. The recovery of pain threshold from OXA-induced hypersensitivity is reported in Figure 4 and Table S2 (see Supporting Information), in which it is clearly seen that ADM_09 reverts the decrease of pain threshold in a dose-dependent manner.

The statistically significant effect could be observed for over 45 min after the administration, with a maximum efficacy at 30 min, whereas at the higher dose (120 mg/kg, p.o.) it persisted for up to 120 min after administration. At a dose of 30 mg/kg, over 70% of the normal pain threshold was recovered after 30 min, while no recovery at all was observed in the absence of ADM_09. At the same dose, the diastereomerically pure compounds RADM_09 and SADM_09 showed only slightly different activities (Fig. 5, Table S2), where RADM_09 appeared to be slightly more effective than SADM_09; however, the most relevant evidence was that both compounds were not significantly different from their mixture, validating the results from tests obtained with ADM_09.

It is noteworthy that neither lipoic acid nor carnosine at a dose of 30 mg/kg could revert OXA-induced NeP to more than a negligible extent; the same was true for their 1:1 combination at the same dose (Fig. 5, Table S2). This evidence clearly demonstrates that ADM_09 possess antihyperalgesic properties not shared by its constituting components; furthermore, the antioxidative tests described above suggest that the relief of NeP observed for treatment with ADM_09 cannot be ascribed to the antioxidative and ROS scavenging capabilities of its precursors.

Cold allodynia, the hypersensitivity to cold temperatures, was described as a characteristic symptom in platin-treated patients. In the present model of chemotherapy-induced neuropathy, on the day 21, oxaliplatin induced a decrease of pain threshold that could also be assessed by the cold plate test. After the administration per os to the treated rats of 30 mg/kg ADM_09, the hypersensitivity to cold temperatures was followed at intervals from 15 to 120 min. The
resulting licking latency is reported in Figure 6 and Table S3 (Supporting Information), showing that a pain-reliever effect was already significant 15 min after treatment and persisted up to 60 min, with a maximum effect between 30 and 45 min. The results clearly show that the reduction in the licking latency to a non-noxious cold stimulus was effectively reverted by administration of ADM_09.

It should be emphasized that, at 30 mg/kg, ADM_09 does not modify the normal behaviour in rats, as revealed by the lack of reduction of the motor coordination observable on rota-rod test.

Toxicity. Toxicity is a crucial property for a promising antineuropathic compound. The toxicity of ADM_09 was tested in vitro on a primary culture of rat astrocytes. Cell viability was assessed as mitochondria functionality by MTT assay, incubating the cell cultures for 24 and 48 h in the presence of increasing amounts of ADM_09. The resulting cell viabilities, with respect to control in the absence of ADM_09, are reported in Figure 7 and Table S5 (Supporting Information) and clearly show the absence of any toxic effect on the astrocyte cultures.

Cardiotoxicity was thus tested in vitro by recording whole-cell currents through HEK293 cells expressing hERG channels (Fig. 8). In the presence of 30 μM ADM_09, the measured outward current was reduced by 14.7 ± 5.4% with respect to the pure vehicle, indicating an IC₅₀ > 30 μM. According to a general system for ranking the inhibitory potency toward the hERG channel, compounds showing IC₅₀ values larger than 10 μM are considered non-cardiotoxic. Thus, the hERG assay demonstrates that ADM_09 is largely above the toxicity threshold.

ADM_09 is a TRPA1 antagonist. Because of the putative role of TRPA1 in OXA-induced hyperalgesia and cold allodynia, our attention was focused on this sensor channel. The TRPA1 channel is activated by several mechanisms and has been actively investigated as a target to control NeP30,31. A chemical activation mechanism of TRPA1 as a nociceptive sensor involves the interaction of its cysteine

Figure 5 | Effect of ADM_09, RADM_09, and SADM_09 on pain threshold recovery from OXA-induced hypersensitivity. Rats were treated daily with OXA (2.4 mg/kg, i.p.). A time-dependent reduction in the mechanical paw-withdrawal threshold was produced. The response to the noxious mechanical stimulus was evaluated at day 21 by the paw-pressure test. At time 0, pure vehicle [1% carboxymethylcellulose (CMC)] or individual compounds were administered per os at the dose of 30 mg/kg. (±) Lipoic acid, L-carnosine, and their 1:1 mixture were also administered as reference compounds. Each value is the mean from 12 rats per group, recorded in 2 different set. *P < 0.01 versus oxa + vehicle-treated rat.

Figure 6 | Effect of ADM_09 on OXA-induced cold allodynia. Rats were treated daily intraperitoneally with oxaliplatin (2.4 mg/kg, i.p.). A time-dependent reduction in the licking latency to a cold non-noxious stimulus was produced. The response was evaluated at day 21 by the cold plate test. At time 0, pure vehicle [1% carboxymethylcellulose (CMC)] or 30 mg/kg ADM_09 were administered per os. Each value is the mean from 6 rats per group, recorded in 2 different set. *P < 0.05 and **P < 0.01 versus OXA + vehicle-treated rats.

Figure 7 | Effect of ADM_09 on astrocyte cell viability. Astrocytes (104 cells/well) were incubated with ADM_09 (1 – 1000 μM) for 24 and 48 hours. Viability was quantified by MTT assay. Absorbance was measured at 550 nm. Values are expressed in percentage of control absorbance as a mean ± s.e.m. of 6 experiments. Control values: 100.0 ± 2.4 (24 h); 100.0 ± 2.9 (48 h).
The variation of the K⁺ represents the mean ± SEM of n > 5 cells.

residues with reactive compounds, which causes the opening of the channel. Because the ADM₀₉ disulphide bridge may react with the thiol groups of TRPA1 cysteine residues, to shed light on the origin of the antihyperalgesic properties of ADM₀₉, the interaction with TRPA1 was investigated through whole-cell patch-clamp recordings. Chinese Hamster ovary (CHO) cells, transfected to overexpress mTRPA1 from mice, were treated by perfusion with OXA, with ADM₀₉, and with well-known activators and blockers of TRPA1 as reference competitors. Both, covalent (allyl isothiocyanate from mustard oil – MO) and noncovalent (menthol) activators were selected for testing, while HC-030031 was employed as the most widely used noncovalent blocker. The above compounds were independently fed to the cell culture at discrete intervals, recording the resulting whole-cell current measured for membrane potential ramps from −100 to +100 mV. In the case of TRPA1, it has been shown that the observed current is mainly due to a flux of Na⁺ and Ca²⁺ ions through the channel, flowing inward for negative potentials (i.e., under physiological conditions) and outward for positive potentials. Because the TRPA1 channel is voltage-dependent, currents were sampled at membrane potentials of +50 and −50 mV in all the experiments. The time courses obtained for the whole-cell current and the corresponding voltage ramps are reported in Figure 9 and Figure S1 (Supporting Information), respectively, in which the compounds perfused, their concentration, and the perfusion time intervals are indicated.

When MO is administered (Fig. 9A), a current increase is observed for both positive and negative potentials, which is driven to zero by perfusion of ADM₀₉. Similarly, a current is recorded when menthol is administered, which is damped when ADM₀₉ is added (Fig. 9B). Clearly, ADM₀₉ behaves as an antagonist of the channel, blocking the stimulated currents caused by the activators administered. In this phenomenology some features are noteworthy: (a) current traces are symmetrical with respect to positive and negative membrane potentials, showing that the channel is gated the same way in both, the inward and the outward directions; (b) current is fully depleted by ADM₀₉, whereas it is non-zero before activation; (c) most importantly, the channel does not re-activate if the activator is fed after the perfusion of ADM₀₉ has been suspended. Apparently, the blocking effect of ADM₀₉ persists beyond the time of administration, a feature that is not observed when HC-030031 is the antagonist employed (the actual persistence of the blocking effect has been observed for at least 10 min after the perfusion of ADM₀₉ has been suspended). Indeed, administration of HC-030031 after activation with MO (Fig. 9C) or menthol (Fig. 9D) blocks the channel for the time of perfusion, but re-activation is immediately observed if the administration is suspended while the activator keeps being fed. Note that the initial current is restored by HC-030031, rather than fully depleted, as with ADM₀₉. In Figure 9E and 9F, the dose-response curves for the inhibition of MO-induced and menthol-induced currents by ADM₀₉ are reported, respectively; the corresponding IC₅₀ values are 13.2 ± 0.5 μM and 10.3 ± 1.7 μM, respectively, showing with excellent agreement a remarkably effective blocking activity of ADM₀₉ toward the TRPA1 channel.

To relate the TRPA1 blocking activity of ADM₀₉ with the observed antihyperalgesic effects, whole-cell currents caused by the administration of OXA were recorded. The corresponding time courses and voltage ramps are reported in Figure 10 and S2 (Supporting Information), respectively.

In Figure 10A, a steep rise of the current is observed after perfusion of OXA, which is driven to zero in 100 s by the administration of ADM₀₉. Clearly, OXA activates TRPA1, whereas ADM₀₉ exerts a channel blocking effect on the OXA-induced currents (a direct chemical reaction of ADM₀₉ with OXA can be ruled out on the basis of ¹H NMR spectra, showing the absence of any spectral variation after 24 h when mixing the two compounds in water at room temperature). Consistently, as observed with MO and menthol, the channel is not re-activated when perfusion of ADM₀₉ is suspended, even under continuing administration of OXA; this evidence confirms that ADM₀₉ acts as an antagonist steadily reverting the OXA-induced noxious effects. In agreement with this evidence, preincubation of TRPA1-expressing cells with ADM₀₉ renders the channel insensitive to OXA administration (Fig. 10B). Interestingly, TRPA1 activation is restored when the blocked channel is treated with dithiothreitol (DTT), a standard reducing agent of disulphide bridges; the restored current is again turned off by ADM₀₉ administration. This sequence of events demonstrates that ADM₀₉-induced blockage is reversible, and can be reverted by reducing agents.

It is known that human and rodent TRPA1 homologues display striking differences in their activities. Often, compounds showing antagonistic effect with human TRPA1 can behave as agonists or show no activity in rat and mouse¹,²,⁵. To validate the results obtained on mTRPA1, wild-type human hTRPA1-expressing CHO were tested by treatment with OXA. The current traces and the voltage ramps recorded as whole-cell currents, reported in Figure 10C and S2C, respectively, demonstrate that the behavior of ADM₀₉ toward the two TRPA1 homologues is strictly analogous, showing channel opening by OXA and blockage by ADM₀₉ that persists under continuing perfusion of OXA.

Because the activity-restoring effect of DTT suggests that the disulphide bridge of lipoic acid may be involved in the blocking activity of ADM₀₉, independent administration of equimolar amounts of L-carnosine and (±) α-lipoic acid were performed while continuously feeding OXA. The current traces and the voltage ramps recorded as whole-cell currents, reported in Figure 10C and S2C, respectively, demonstrate that the behavior of ADM₀₉ toward the two TRPA1 homologues is strictly analogous, showing channel opening by OXA and blockage by ADM₀₉ that persists under continuing perfusion of OXA.

Figure 8 | Effect of 30 μM ADM₀₉ on hERG channels expressed in HEK293 cells. The outward current reduction was 14.7 ± 5.4% with respect to pure vehicle. hERG currents were elicited using a hyperpolarizing pre-pulse to −80 mV, followed by a voltage step from −60 to +40 mV for 500 ms, a step to −50 mV for 250 ms, and back to holding. The variation of the K⁺ current at +40 mV is reported. Each column represents the mean ± SEM of n > 5 cells.
a Ca\(^{2+}\)-containing solution of ADM_09 (Fig. 10E). Thus, the blocking properties of ADM_09 are modulated by the Ca\(^{2+}\) concentration. In contrast, as a control reference, the described behavior is not evoked by HC-030031 on MO-activated TRPA1 (Figs. 10F and S2F), which is insensitive to the absence of calcium ions.

Finally, the different antihyperalgesic activity observed in vivo for the two diastereomeric structures of ADM_09, featuring the R diastereomer slightly more effective than the S isomer, was checked by recording the whole-cell currents through mTRPA1 after activation by OXA and blockage with RADM_09 and SADM_09. The

---

**Figure 9** | Representative time courses of whole-cell currents through mTRPA1-expressing CHO, measured at membrane potential of +50 mV (black curve) and −50 mV (grey curve) during administration of A) MO and ADM_09; B) Menthol and ADM_09; C) MO and HC030031; D) Menthol and HC030031 at the indicated concentrations and time intervals. E) Dose-response curve for the inhibition of 100 μM MO-induced currents by ADM_09. The corresponding IC\(_{50}\) value is 13.2 ± 0.5 μM. F) Dose-response curve for the inhibition of 100 μM menthol-induced currents by ADM_09. The corresponding IC\(_{50}\) value is 10.3 ± 1.7 μM.
results reported in Figure 11 as normalized currents show that, with respect to OXA, the observed residual current is 3% for RADM_09 and 8% for SADM_09, with an intermediate value of over 4% for their mixture present in ADM_09. It should be appreciated that current data obtained in vitro from the TRPA1 channel closely match the in vivo antihyperalgesic results from the paw-pressure and the cold plate tests, strongly supporting a direct connection between the ability of ADM_09 to revert NeP and its TRPA1 blocking activity.
The nociceptive response.

...with thiol-reacting compounds, which activate the pore near the thiol groups.


gathering all the results presented, a rationale for the blocking activity of ADM_09 can be tentatively puzzled out. TRPA1 is a Ca\(^{2+}\)-permeable non-selective cation channel; its activity is not only calcium-regulated, but also characterized by a large fraction of the inward current being carried by Ca\(^{2+}\). Stimulation by activators, such as MO, induces an increase in the fractional Ca\(^{2+}\) current, suggesting that the pore of TRPA1 is dynamic and supports a surprisingly large Ca\(^{2+}\) influx. In addition, Ca\(^{2+}\) binds to TRPA1, and the putative Ca\(^{2+}\)-binding domain is constituted by acidic residues located in the pore near the C-terminus of the channel. TRPA1 is particularly rich in cysteine residues, that constitute the nucleophilic sites of disulphide bond formation with thiol-reacting compounds, which activate the nociceptive response.

The patch-clamp experiments described in this work have shown that carnosine and the carnosine moiety of ADM_09 are the structural units responsible for blocking the activated TRPA1, although with different efficacy, and that both require Ca\(^{2+}\) ions to exert blocking activity. This evidence is in agreement with the calcium-binding properties of carnosine: under physiological conditions, carnosine forms monomeric (through carboxylate and carbonyl oxygens) and dimeric (through carboxylate, carbonyl oxygens, and imidazole nitrogens) complexes with Ca\(^{2+}\). It is therefore predictable that carnosine may form a ternary complex with Ca\(^{2+}\) and TRPA1, in which carboxylate and imidazole groups from the channel protein would replace one of the two carnosine molecules in the complex, as depicted in Figure 12A. This may explain the calcium-mediated binding of carnosine to the TRPA1 pore; yet, the moderate blocking activity may be ascribed to the intrinsic lability of the complex, as desumed from the moderate affinity reported for the carnosine Ca\(^{2+}\) complex. In contrast, a markedly stronger blocking effect is exerted by ADM_09, and this enhancement can be explained on the basis of the well-established thiol-disulphide chemistry (Fig. 12B).

At physiological pH, thiol groups are converted into disulphides by atmospheric oxygen. This thermodynamically-favored process occurs concomitantly to the thiolate-catalyzed thiol/disulphide equilibration, which scrambles the cysteine thiol groups of the protein with the sulphur atoms of the lipoic acid disulphide groups, thereby anchoring ADM_09 to the channel through disulphide bridges. In this process, the catalytic thiolate anion required for the equilibration is ensured by the imidazolic groups of histidines. Through this pathway, the calcium-binding carnosine moiety is covalently bound to the channel through the lipoic acid residue, and can therefore exert a persistent activity through a synergically stabilized binding to TRPA1. Consistently, ADM_09 can be “washed away” by DTT, which reverts the disulphide bridging to the channel by restoring the proteic cysteine thiol groups and the disulphide moiety of lipoic acid. The activation/blocking cycle is depicted in the scheme of Figure 13. Note that even in the presence of Ca\(^{2+}\), lipoic acid alone is incapable of blocking TRPA1, whereas in the absence of Ca\(^{2+}\), ADM_09 is devoid of any blocking activity as well, although disulphide anchoring is most likely occurring in both cases. Thus, ADM_09 is a dual-binding calcium-dependent blocker of TRPA1 in that the Ca\(^{2+}\)-binding carnosine and the lipoic acid disulphide are both essential requirements for activity.

The actual blocking mechanism by which the bound ADM_09 can prevent the current from flowing through the channel has yet to be elucidated, although allosteric modifications of the pore induced by the significant size of the bound structure may represent a reasonable working hypothesis. Nevertheless, a phenomenological aspect of the mode of action we propose deserves a comment. It is generally accepted that disulphide-bond-forming reactive compounds cause activation of the TRPA1 channel by covalent modification of reactive cysteines, whereas channel blocking is induced by the reducing agent dithiotreitol.

**Figure 11** Pooled-data of whole-cell currents through mTRPA1-CHO transfected cells measured at membrane potential of +50 mV, activated by oxaliplatin 100 nM (OXA, black) and blocked by ADM_09 (white), RADM_09 (grey) and SADM_09 (hatched) 30 nM each. Each column is the mean ± SEM of n > 5 cells. Values are normalized to OXA-activated current. Whole-cell currents were elicited by 400 ms voltage ramps from -100 to +100 mV. The residual TRPA1 current was 4.4 ± 1.3% for ADM_09; 3.1 ± 1.7% for RADM_09; and 7.7 ± 3.5% for SADM_09, respectively.

**Discussion**

Gathering all the results presented, a rationale for the blocking activity of ADM_09 can be tentatively puzzled out. TRPA1 is a Ca\(^{2+}\)-permeable non-selective cation channel; its activity is not only calcium-regulated, but also characterized by a large fraction of the inward current being carried by Ca\(^{2+}\). Stimulation by activators, such as MO, induces an increase in the fractional Ca\(^{2+}\) current, suggesting that the pore of TRPA1 is dynamic and supports a surprisingly large Ca\(^{2+}\) influx. In addition, Ca\(^{2+}\) binds to TRPA1, and the putative Ca\(^{2+}\)-binding domain is constituted by acidic residues located in the pore near the C-terminus of the channel. TRPA1 is particularly rich in cysteine residues, that constitute the nucleophilic sites of disulphide bond formation with thiol-reacting compounds, which activate the nociceptive response.

The patch-clamp experiments described in this work have shown that carnosine and the carnosine moiety of ADM_09 are the structural units responsible for blocking the activated TRPA1, although with different efficacy, and that both require Ca\(^{2+}\) ions to exert blocking activity. This evidence is in agreement with the calcium-binding properties of carnosine: under physiological conditions, carnosine forms monomeric (through carboxylate and carbonyl oxygens) and dimeric (through carboxylate, carbonyl oxygens, and imidazole nitrogens) complexes with Ca\(^{2+}\). It is therefore predictable that carnosine may form a ternary complex with Ca\(^{2+}\) and TRPA1, in which carboxylate and imidazole groups from the channel protein would replace one of the two carnosine molecules in the complex, as depicted in Figure 12A. This may explain the calcium-mediated binding of carnosine to the TRPA1 pore; yet, the moderate blocking activity may be ascribed to the intrinsic lability of the complex, as desumed from the moderate affinity reported for the carnosine Ca\(^{2+}\) complex. In contrast, a markedly stronger blocking effect is exerted by ADM_09, and this enhancement can be explained on the basis of the well-established thiol-disulphide chemistry (Fig. 12B).

At physiological pH, thiol groups are converted into disulphides by atmospheric oxygen. This thermodynamically-favored process occurs concomitantly to the thiolate-catalyzed thiol/disulphide equilibration, which scrambles the cysteine thiol groups of the protein with the sulphur atoms of the lipoic acid disulphide groups, thereby anchoring ADM_09 to the channel through disulphide bridges. In this process, the catalytic thiolate anion required for the equilibration is ensured by the imidazolic groups of histidines. Through this pathway, the calcium-binding carnosine moiety is covalently bound to the channel through the lipoic acid residue, and can therefore exert a persistent activity through a synergically stabilized binding to TRPA1. Consistently, ADM_09 can be “washed away” by DTT, which reverts the disulphide bridging to the channel by restoring the proteic cysteine thiol groups and the disulphide moiety of lipoic acid. The activation/blocking cycle is depicted in the scheme of Figure 13. Note that even in the presence of Ca\(^{2+}\), lipoic acid alone is incapable of blocking TRPA1, whereas in the absence of Ca\(^{2+}\), ADM_09 is devoid of any blocking activity as well, although disulphide anchoring is most likely occurring in both cases. Thus, ADM_09 is a dual-binding calcium-dependent blocker of TRPA1 in that the Ca\(^{2+}\)-binding carnosine and the lipoic acid disulphide are both essential requirements for activity.

The actual blocking mechanism by which the bound ADM_09 can prevent the current from flowing through the channel has yet to be elucidated, although allosteric modifications of the pore induced by the significant size of the bound structure may represent a reasonable working hypothesis. Nevertheless, a phenomenological aspect of the mode of action we propose deserves a comment. It is generally accepted that disulphide-bond-forming reactive compounds cause activation of the TRPA1 channel by covalent modification of reactive cysteines, whereas channel blocking is induced by the reducing agent dithiotreitol.

**Figure 12** (A) Interaction of carnosine residues with Ca\(^{2+}\) ions and carboxylate and imidazole groups from TRPA1, leading to a ternary complex. (B) Thiolate-catalyzed disulphide bridge formation between TRPA1 cysteines and lipoic acid disulphide. The reaction is reversed by reduction with dithiotreitol.

...with thiol-reacting compounds, which activate the pore near the thiol groups.
DTT. In our results, the opposite seems to occur, whereby disulphide bond formation causes deactivation of TRPA1, whereas DTT restores the native form of the channel that is activated by OXA. This apparent discrepancy can be rationalized considering that the actual blocking effect is due to the calcium-mediated binding of carnosine, where the disulphide bridges merely exert the function of anchoring ADM_09 to the proteic backbone. It should also be considered that, most likely, the cysteines involved in the anchoring of ADM_09 are different from those involved in the activation of the channel. Indeed, when anchoring lipoic acid, or ADM_09 in the absence of Ca\(^{2+}\), on TRPA1 activated with MO, no blocking effect is observed, indicating that the two disulphide-forming reactants do not interfere with each other.

Concluding, in the present work we have shown that ADM_09, obtained by coupling L-carnosine with \(\alpha\)-lipoic acid, can effectively revert neuropathic pain evoked by chemotherapeutic agents, such as oxaliplatin, without eliciting the most common negative side-effects observed in pain treatment. While exhibiting reduced antioxidative properties with respect to the parent lipoic acid, ADM_09 showed a marked efficacy in neuropathic pain control in vivo, which was lacking in both the parent constituents. Most importantly, ADM_09 did not modify the normal behavior in rat, and did not show any toxicity toward astrocyte cell viability, nor any relevant cardiotoxicity, as revealed by the human ERG channel test. Patch-clamp experiments demonstrated that ADM_09, in contrast to both L-carnosine and \(\alpha\)-lipoic acid, is a TRPA1 antagonist capable of blocking currents evoked by several covalent and noncovalent activators, including oxaliplatin, thus reverting the neuropathic response. A rationale for the observed blocking activity has been proposed, according to which the persistent antagonistic effect of ADM_09 toward TRPA1 is caused by a synergic combination of a deactivating calcium-mediated binding of the carnosine residue and of a covalent anchoring of the lipoic acid residue to the cysteines of the channel protein. It should be emphasized that the antagonistic effects of ADM_09 on the human TRPA1 variant are strictly analogous to those observed in the experiments with the rodent homologues. Although the actual mechanism of action has yet to be established, the findings reported in this work open the way to the development of a new generation of compounds for neuropathic pain control.

**Methods**

**Cell Viability Assay.** Cell viability was evaluated by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as an index of mitochondrial compartment functionality. Primary astrocytes were plated into 96 well cell culture plates, grown until confluence and treated for 24 and 48 hours with different concentrations of ADM_09 in DMEM. After extensive washing, 1 mg/mL MTT was added into each well and incubated for 2 hours at 37 °C. After washing, the formazan crystals were dissolved in 100 µL dimethyl sulfoxide. The absorbance was measured at 580 nm. Experiments were performed in quadruplicate on at least 3 different cell batches.

**Animals.** Male Sprague-Dawley rats (Harlan, Varese, Italy) were used, weighing approximately 200–250 g at the beginning of the experimental procedure. The animals were housed in CeSAL (Centro Stabulazione Animali da Laboratorio, University of Florence) and used at least one week after their arrival. Four rats were housed per cage (size 26 × 41 cm); the animals were fed with standard laboratory diet and tap water ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All animal manipulations were carried out according to the European Community guidelines for animal care (DL 116/92, application of the European
CHO cell culture. We used a tetracycline-regulated system for inducible expression of mouse TRPA1 in CHO (Chinese-Hamster Ovary) cells as previously reported. To induce expression of TRPA1, 1 μg/ml tetracycline was added to the culture medium, and cells were used 2–3 h after induction.

1. Sherrington, C. S. Observation on the scratch-reflex in the spinal dog. J. Physiol. 34, 1–50 (1905).
2. Woolf, C. J. & Mannion, R. J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353, 1959–1964 (1999).
3. Gilron, I., Watson, C. P., Cahill, C. M. & Moulin, D. E. Neuropathic pain: a practical guide for the clinician. Can. Med. Ass. J. 175, 265–275 (2006).
4. Baron, R. Mechanisms of disease: neuropathic pain–a clinical perspective. Nat. Clin. Pract. Neurol. 2, 95–106 (2006).
5. White, F. A., Jung, H. & Miller, R. J. Chemokines and the pathophysiology of neuropathic pain. Proc. Natl. Acad. Sci. USA 104, 20151–20158 (2012).
6. Watson, C. P. The treatment of neuropathic pain: antidepressants and opioids. N. Engl. J. Med. 343, 1563–5 (2000).
7. Hempenstall, K. et al. Analgesic therapy in postherpetic neuralgia: a systematic review. Pain 82, S38–46 (2005).
8. Kennedy, J. D. Neuropathic pain molecular complexity underlines continuing unmet medical need J. Med. Chem. 50, 2547–2556 (2007).
9. Grothey, A. Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer 1, S38–46 (2005).
10. Cersosimo, R. J. Oxaliplatin-associated neuropathy: a review. Ann. Pharmacother. 39, 128–35 (2005).
11. Andreade, E. L., Mesiti, F. C. & Calixto, J. B. TRPA1 antagonists and potential drugs. Pharmacology & Therapeutics 133, 189–204 (2012).
12. Kiernan, M. C. The pain with platinum: oxaliplatin and neuropathy. Eur. J. Cancer 43, 2631–2633 (2007).
13. Argyriou, A. A., Bruna, J., Marniiri, P. & Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 82, 51–77 (2012).
14. Gauchan, P., Andoh, T., Kato, A. & Kuraishi, Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci. Lett. 458, 93–95 (2009).
15. Nassini, R. et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152, 1621–1631 (2011).
16. Descoeur, J. et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 3, 266–278 (2011).
17. Anderson, D. W. et al. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced Parkinsonism. Eur. J. Neurosci. 28, 610–617 (2008).
18. Nativi, C., Ghelardini, C. & la Marca, G. Compounds with both analgesic and anti-hyperalgesic efficacy. PCT/B2011/050018.
19. Saada, M. C. et al. Carbonic anhydrase activators: gold nanoparticles coated with derivatized histamine, histidine, and carnosine show enhanced activevies effects on several mammalian isoforms. J. Med. Chem. 54, 1170–1177 (2011).
20. Parcker, L., Witt, E. H. & Tritschler, H. J. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol. Med. 19, 227–230 (1995).
21. Joseph, E. K., Chen, X., Bogen, O. & Levine, J. D. Oxaliplatin on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J. Pain 9, 463–472 (2008).
22. Hipkiss, A. R. Carnosine and its possible roles in nutrition and health. Adv. Food Nutr. Res. 57, 87–154 (2009).
23. Lipinska, C. A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting Adv. Drug Delivery Reviews 23, 3–25 (1997).
24. Scholz, J. & Woolf, C. J. The neuropatic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, 1361–1368 (2007).
25. Cavalletti, G. et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer 37, 2457–2463 (2001).
26. Kannarkat, G., Lasher, E. E. & Schiff, D. Neurologic complications of chemotherapy agents. Current Opinion in Neurology 20, 719–725 (2007).
27. Wolf, S. et al. Chemotherapy induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer 44, 1507–1515 (2008).
28. Mitcheson, J. S. et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA 97, 12329–12333 (2000).
29. Roche, O. et al. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries. ChemBioChem 3, 455–9 (2002).
30. Nilius, B., Appendino, G. & Owsianski, G. The transient receptor potential channel TRPA1: from gene to pathophysiology Pflugers Arch –Eur J Physiol 464, 425–458 (2012).
31. Karashima, Y. et al. TRPA1 acts as a cold sensor in vitro and in vivo. Proc. Natl. Acad. Sci. USA 106, 1273–1278 (2009).
32. Karashima, Y. et al. Agonist-induced changes in Ca2+ permeation through the nociceptor cation channel TRPA1. Biophysical J. 98, 773–783 (2010).
33. Zygmunt, P. M. A TRP(i)P in the air. Nature Chemical Biology 7, 661–663 (2011).
34. Gaggioli, E. & Valensin, G. H+ and Ca2+ NMR Relaxation Investigation of the calcium complex of beta-alanyl-L-histidine (carnosine) in aqueous solution. J. Chem. Phys. Trans. 2, 401–406 (1990).

Acknowledgments
We are grateful to prof. Pierangelo Geppetti (University of Florence) for providing mouse TRPA1 CHO stably transfected cells and HC030031, to prof. David Julius (UCSF, CA USA) for providing human TRPA1 wild-type cDNA and to prof. Annarosa Arcangeli (University of Florence) for the kind gift of HEK 293 cells stably expressing hERG channel. This work was supported by the Ministero dell’Istruzione, dell’Università e della Ricerca, AIRC and the Ente Cassa di Risparmio di Firenze.

Author contributions
C.N., C.G., M.R.M. and S.R. designed research; R.G., E.D., L.D.C.M., S.S., M.N., G.G., G.l.M., B.R. and O.F. performed research; C.N., C.G., R.G. and S.R. analyzed data and C.N. and S.R. wrote the paper.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/srep.

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Nativi, C. et al. A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci. Rep. 3, 2005; DOI:10.1038/srep02005 (2013).